Alchemab Therapeutics, a biotech company developing novel products for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, today announces the completion of a £60 million ($82 million) Series A financing round.

Alchemab has developed a highly differentiated platform which enables the identification of novel drug targets and therapeutics on the basis of patient B-cell antibody repertoires. The platform uses well-defined patient samples and a range of functional and advanced analytical techniques to evaluate convergent protective antibody responses in groups of individuals that are susceptible but resilient to specific diseases.

Alchemab Raises £60M ($82M) In Series A Financing To Advance Novel Platform For Identifying Disease-Modifying Antibody Therapeutics

Description

Company Information

Funding Insights

Alchemab Raises £60M ($82M) In Series A Financing To Advance Novel Platform For Identifying Disease-Modifying Antibody Therapeutics

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information